麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02335 麦科医药-B

交易中 07-09 10:02:32

41.980

+0.880

+2.14%

最高42.840	最低41.120	成交量15.84万
今开41.120	昨收41.100	日振幅4.18%
总市值139.26亿	流通市值117.57亿	总股本3.32亿
成交额659.06万	换手率0.06%	流通股本2.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02335","market":"HK","secType":"STK","nameCN":"麦科医药-B","latestPrice":41.98,"timestamp":1783562551395,"preClose":41.1,"halted":0,"volume":158400,"delay":0,"changeRate":0.02141119221411181,"floatShares":280071100,"shares":331740350,"eps":0,"marketStatus":"交易中","change":0.88,"latestTime":"07-09 10:02:32","open":41.12,"high":42.84,"low":41.12,"amount":6590572,"amplitude":0.041849,"askPrice":41.98,"askSize":2200,"bidPrice":41.92,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.609,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1783569600000},"marketStatusCode":2,"adr":0,"listingDate":1782230400000,"exchange":"SEHK","adjPreClose":41.1,"openAndCloseTimeList":[[1783560600000,1783569600000],[1783573200000,1783584000000]],"volumeRatio":2.875694,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02335","defaultTab":"news","newsList":[{"id":"2649605077","title":"港股异动 | 麦科医药-B(02335)午前涨超3% MT1002治疗急性缺血性卒中Ib/II期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2649605077","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649605077?lang=zh_cn&edition=full","pubTime":"2026-07-07 11:44","pubTimestamp":1783395880,"startTime":"0","endTime":"0","summary":"消息面上，麦科医药-B发布公告，本集团自主研发的候选药物MT1002用于治疗急性缺血性卒中的Ib/II期临床试验，近日已成功完成首例受试者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。第一部分为一项在急性缺血性卒中患者中评价MT1002安全性、有效性和药代动力学特征的多中心临床研究。本公告所述首例受试者入组，乃本项Ib/II期临床试验第一部分的首例受试者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","IBBQ","BK4585","BMED","KCAI","BK4588","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143530039","title":"麦科医药-B 2026年6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1143530039","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143530039?lang=zh_cn&edition=full","pubTime":"2026-07-06 20:01","pubTimestamp":1783339270,"startTime":"0","endTime":"0","summary":"陕西麦科奥特医药科技股份有限公司于2026年7月6日发布截至2026年6月30日止6月股份变动月报表。报告显示，公司本月股本整体维持稳定，未出现新增发行、购回或注销股份情形。具体来看，截至2026年6月30日，麦科医药-B已发行的H股股份数量为280,071,100股，内资股股份数量为51,669,250股，均与上月底持平，公司存续股份总数为331,740,350股。H股的最低公募持股比例为24.84%，且公司已确认达到适用的最低公众持股量要求。本次月报由执行董事王冰签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648668245","title":"麦科医药-B(02335)：MT1002治疗急性缺血性卒中Ib/II期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668245","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648668245?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:32","pubTimestamp":1783074725,"startTime":"0","endTime":"0","summary":"智通财经APP讯，麦科医药-B 发布公告，本集团自主研发的候选药物MT1002用于治疗急性缺血性卒中的Ib/II期临床试验，近日已成功完成首例受试者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。本项Ib/II期临床试验分为两部分。第一部分为一项在急性缺血性卒中患者中评价MT1002安全性、有效性和药代动力学特征的多中心临床研究。本公告所述首例受试者入组，乃本项Ib/II期临床试验第一部分的首例受试者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","IBBQ","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648510265","title":"18A亦有差距，麦科医药-B(02335)何以锚定港股通短期快速纳入红利？","url":"https://stock-news.laohu8.com/highlight/detail?id=2648510265","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648510265?lang=zh_cn&edition=full","pubTime":"2026-07-01 19:47","pubTimestamp":1782906477,"startTime":"0","endTime":"0","summary":"得益于港股通短期快速纳入机制，今年6月下旬以来，港股有超10家来自不同行业的公司抢抓“入通”黄金窗口期集中登陆港市。麦科医药-B便是其中之一。华健未来和麦科医药这两家18A企业正是在低迷的场内情绪中分别于6月23日和6月24日挂牌上市。另外，其释出的公开发售数量为29028手，入场费为4242.36港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02335","BK4585","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02670","02726","BK4585","01511","02672","07630","02696","06675","00068","00340","03310","02272","03625","01236","02553","06656","02335","BK4588","01191","03355","01021","01392","01956","02616","02723","01286","06872","09630","00863","01866","03388","02526","07666","01609","01133","00376","06106","01081","02142","06938","03887","01651","00600","03661","07688","02632","06658","01779","03277","02729","09637","06636","00100","00412","01440","01672","01879"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1178096326","title":"异动解读｜麦科医药-B盘中下跌5.03%，上市第五个交易日获利盘持续释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1178096326","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178096326?lang=zh_cn&edition=full","pubTime":"2026-06-30 15:49","pubTimestamp":1782805789,"startTime":"0","endTime":"0","summary":"6月30日，麦科医药-B盘中下跌5.03%，报36.6港元，成交额2841.26万港元。消息面上，该股于6月24日以18.20港元发行价登陆港交所，首日大涨102.75%，香港公开发售获1181.46倍超额认购，上市后股价最高触及40港元水平，较发行价涨幅超一倍。前期连续快速拉升积累大量浮盈筹码，此前6月26日及6月29日已连续出现类似回调走势，获利回吐压力延续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120351381","title":"麦科医药：西北药王笃定中国创新药！7年磨一剑穿越周期登陆港股","url":"https://stock-news.laohu8.com/highlight/detail?id=1120351381","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120351381?lang=zh_cn&edition=full","pubTime":"2026-06-29 09:54","pubTimestamp":1782698094,"startTime":"0","endTime":"0","summary":"图片2026年6月24日，香港联交所铜锣敲响——麦科医药-B正式挂牌上市，成为港股18A多肽创新药第一股、中国西北地区首家18A创新药企。2025年全球两大GLP-1多肽药物合计销售额突破700亿美元，赛道长期增长确定性明确。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/E94tCrfkcV3YnoYdntiNDA?click_id=2136877367","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1610162075297","symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148562581","title":"异动解读｜麦科医药-B盘中下跌7.89%，上市第四个交易日获利盘持续涌出","url":"https://stock-news.laohu8.com/highlight/detail?id=1148562581","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148562581?lang=zh_cn&edition=full","pubTime":"2026-06-29 09:54","pubTimestamp":1782698088,"startTime":"0","endTime":"0","summary":"6月29日，麦科医药-B盘中下跌7.89%，报38.06港元，成交额195.38万港元。消息面上，该股于6月24日以18.20港元发行价登陆港交所，首日大涨102.75%，香港公开发售获1181.46倍超额认购，上市后股价最高触及40港元水平，较发行价涨幅超一倍。作为一家依据18A规则上市的未盈利生物科技企业，公司核心产品MT1013仍处于III期临床阶段，预计2028年初方可商业化，短期无营收贡献。前期连续快速拉升积累大量浮盈筹码，获利回吐压力延续，此前6月26日已出现类似调整走势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126180500","title":"异动解读｜麦科医药-B盘中下跌6.28%，上市第三日高位回调获利盘涌出","url":"https://stock-news.laohu8.com/highlight/detail?id=1126180500","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126180500?lang=zh_cn&edition=full","pubTime":"2026-06-26 09:32","pubTimestamp":1782437523,"startTime":"0","endTime":"0","summary":"6月26日，麦科医药-B盘中下跌6.28%，报37.38港元，成交额27.03万港元。消息面上，该股于6月24日以18.20港元发行价登陆港交所，首日大涨102.75%收报36.9港元，香港公开发售获1181.46倍超额认购，上市后股价持续走高至近40港元水平。作为一家仍处研发投入阶段的18A生物科技企业，公司核心产品MT1013尚处于III期临床阶段，预计2028年初方可商业化，短期无营收贡献。前期连续快速拉升后，获利回吐压力显现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106756302","title":"西北首家18A生物科技股麦科医药-B携多肽矩阵登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=1106756302","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106756302?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:52","pubTimestamp":1782355970,"startTime":"0","endTime":"0","summary":"6月24日，陕西麦科奥特医药科技股份有限公司在港交所主板挂牌上市，成为“港股多肽创新药第一股”，同时也是西北地区首家依据18A规则上市的生物科技企业。该股发行价定为18.20港元，开盘后迅速拉升，截至当日收盘，股价报36.9港元，涨幅达102.75%，全天成交活跃，市场资金追捧热度显著。本次全球发售共5805.44万股，扣除相关费用后所得款项净额约10.56亿港元。在商业化方面，麦科医药已提前布局。","market":"us","thumbnail":"https://community-static.tradeup.com/news/5571eaa8cbe19d65a93af4066637d9ea","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/5571eaa8cbe19d65a93af4066637d9ea"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197299971","title":"麦科医药上市，中国多肽药物告别“跟随时代”","url":"https://stock-news.laohu8.com/highlight/detail?id=1197299971","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197299971?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:46","pubTimestamp":1782355586,"startTime":"0","endTime":"0","summary":"6月24日，麦科医药正式港股上市，首日市场表现强劲，收盘价报36.9港元，涨幅超100%，彰显出资本市场对其多肽药物创新布局的认可和期待。此外，目前所有主流SHPT药物均为小分子药物，MT1013作为多肽药物，能够避免小分子药物的严重胃肠道不良反应，且可与透析同时给药，从而提供患者依从性，扩大合资格患者群。","market":"us","thumbnail":"https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/i8EL2OlCbqMv2ol1oZzYyA","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1571747680734","symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645401865","title":"麦科医药香港上市首日涨超90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645401865","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645401865?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:18","pubTimestamp":1782267508,"startTime":"0","endTime":"0","summary":"麦科医药香港上市首日涨超90%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606243780977297.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243780977297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02335","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645865253","title":"港股速报 | 港股迎来反弹，恒科涨超1% 机构建议：未来把握三条主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2645865253","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645865253?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:59","pubTimestamp":1782266399,"startTime":"0","endTime":"0","summary":"今日（6月24日），港股市场经过连续下跌之后，终于迎来小幅反弹。早间开盘，恒生指数报23420.70点，高开84.42点，涨幅0.36%；恒生科技指数开盘报4420.41点，上涨21.19点，涨幅0.48%。开盘之后，恒生科技指数快速拉升，截至发稿，涨幅超过1%。新股方面，今日又有两只新股同时上市。麦科医药-B（HK02335）上市首日高开86%，截至发稿，涨超80%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606243780901441.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243780901441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03033","02335","83115","03423","07300","02837","07500","513600","03032","MHImain","07200","HSTECH","HHImain","03037","HSI","03417","09115","MCHmain","82800","03088","03067","09067","03115","07552","09088","02833","02800","06106","03419","07226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179444712","title":"新股首日 | 麦科医药大升90%，一手账面赚3304港元；仙工智能股价微升","url":"https://stock-news.laohu8.com/highlight/detail?id=1179444712","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179444712?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:35","pubTimestamp":1782264927,"startTime":"0","endTime":"0","summary":"麦科医药、仙工智能今日挂牌：麦科医药大升90%，以每手200股计，一手账面赚3304港元。至于仙工智能股价微升，与招股价几乎持平。麦科医药香港公开发售部分共约15.4万人申请，超额认购约1180.5倍，一手中签率3%，认购1500手始稳获1手。国际发售超购1.5倍。仙工智能香港公开发售部分共有约22.3万人申请，超额认购约5933.6倍，一手中签率5%，认购2000手方稳获一手。国际发售超额认购20.3倍。","market":"hk","thumbnail":"https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3430ee0e05254278b5a3da84a7b77b4c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","06106"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162547441","title":"异动解读 | 麦科医药-B新股首日挂牌盘中大涨89.56%，获超1100倍认购引爆市场热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1162547441","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162547441?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:35","pubTimestamp":1782264920,"startTime":"0","endTime":"0","summary":"麦科医药-B今日盘中大幅上涨89.56%，引起了市场的广泛关注。消息面上，麦科医药-B作为一只新股于今日正式在港交所主板挂牌上市。此次上市获得了市场的热烈追捧，香港公开发售部分获得了高达1181.46倍的超额认购，一手中签率仅为3%，显示出投资者极高的参与热情。市场对其在代谢性疾病及心脑血管领域的研发管线抱有积极预期，这进一步增强了新股上市的投资吸引力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106115115","title":"异动解读｜麦科医药-B盘中上涨89.56%，新股首日挂牌获市场热捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1106115115","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106115115?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:30","pubTimestamp":1782264652,"startTime":"0","endTime":"0","summary":"6月24日，麦科医药-B正式登陆港交所主板，盘中上涨89.56%，报34.5港元，成交额2.18亿港元。消息面上，公司以每股18.2港元定价发行5805.44万股H股，净筹约9.89亿港元。香港公开发售获1181.46倍超额认购，一手中签率仅3%，国际发售获2.52倍认购，市场认购热度极高。此前暗盘阶段股价已大涨超60%，首日开盘价即达34.02港元，较发行价溢价约87%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645697863","title":"新股首日 | 麦科医药-B(02335)首挂上市 早盘高开86.92% 核心产品MT1013正处于III期临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2645697863","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645697863?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:25","pubTimestamp":1782264328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，麦科医药-B首挂上市，公告显示，每股定价18.2港元，共发行5805.44万股股份，每手200股，所得款项净额约10.67亿港元。截至发稿，涨86.92%，报34.02港元，成交额2.17亿港元。公开资料显示，麦科医药已自主开发由一项核心产品及其他六项候选产品组成的产品管线。预计公司的MT1013将于2028年初商业化，公司将实行双轨商业化策略：在国内透过与第三方合约销售组织合作，在国际上则透过授权合作伙伴关系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02335","III","BK4134","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122014729","title":"麦科医药-B香港首秀开盘价定为每股34.02港元 较发行价18.2港元大幅溢价","url":"https://stock-news.laohu8.com/highlight/detail?id=1122014729","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122014729?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:21","pubTimestamp":1782264076,"startTime":"0","endTime":"0","summary":"麦科医药-B的股票在香港交易所首次亮相时，开盘价确定为每股34.02港元。这一价格显著高于其每股18.2港元的发行定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100128924","title":"新股定价 | 麦科医药-B发售价为每股18.2港元，公开发售超购1180.46倍，一手中签率3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100128924","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100128924?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:21","pubTimestamp":1782264069,"startTime":"0","endTime":"0","summary":"麦科医药-B(02335)公布配发结果，公司全球发售约5805.44万股H股，香港公开发售占10%，国际发售占90%。最终发售价为每股18.2港元，全球发售净筹9.89亿港元。每手200股，一手中签率3%，预期H股将于今日(星期三)上午九时正开始在联交所买卖。其中，香港公开发售获1181.46倍认购，国际发售获2.52倍认购。","market":"us","thumbnail":"https://community-static.tradeup.com/news/1a74b44da6cc115f21b7f29f7abc6a77","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/1a74b44da6cc115f21b7f29f7abc6a77"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645306948","title":"麦科医药明日上市：暗盘大涨超90% 市值117亿港元 年亏1.85亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2645306948","media":"雷递网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645306948?lang=zh_cn&edition=full","pubTime":"2026-06-23 23:33","pubTimestamp":1782228815,"startTime":"0","endTime":"0","summary":"陕西麦科奥特医药科技股份有限公司（简称“麦科医药”，股票代码：“02335”）将于明日在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260623/6391785441241009862128851.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260623/6391785441241009862128851.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34122/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["02335","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.micot.cn","stockEarnings":[{"period":"1week","weight":0.1248},{"period":"1month","weight":1.2582},{"period":"ytd","weight":1.2582}],"compareEarnings":[{"period":"1week","weight":0.0576},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0603},{"period":"6month","weight":-0.0775},{"period":"1year","weight":0.0021},{"period":"ytd","weight":-0.0558}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"陕西麦科奥特医药科技股份有限公司(以下简称“麦科奥特”)于2007年1月在西安成立,现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业,致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业,聚焦于心脑血管、代谢性疾病、炎症疼痛相关疾病新药的研发。公司致力于创制新药、挽救生命,满足未被满足的临床需求,用科技创新为人类健康保驾护航。\n麦科奥特作为一家平台型生物技术公司,致力于加速全球新一代双特异性/多特异性多肽药物的创新及开发,我们的核心产品处于Ⅲ期临床试验。自2007年成立以来,我们专注于代谢性疾病(尤其是肾脏相关疾病)以及心脑血管疾病,作为提出双/多特异性肽技术概念的全球先驱,并凭借进入临床开发的广泛候选产品管线,我们已在该领域确立领先地位。","exchange":"SEHK","name":"麦科医药-B","nameEN":"MICOT PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"麦科医药-B,02335,麦科医药-B股票,麦科医药-B股票老虎,麦科医药-B股票老虎国际,麦科医药-B行情,麦科医药-B股票行情,麦科医药-B股价,麦科医药-B股市,麦科医药-B股票价格,麦科医药-B股票交易,麦科医药-B股票购买,麦科医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}